Study protocol for a multicentre, randomised, double-blinded, placebo-controlled, multi-arm, multi-stage, trial of SpironolacTone and famciclOovir in the treatment of Progressive Multiple Sclerosis to prevent disability progression: the STOP-MS trial

20250 citationsJournal Articlediamond Open Access

Authors

Kayla Ward · Griffith University

Vivien Li · Florey Institute of Neuroscience and Mental Health

Sudarshini Ramanathan · Concord Repatriation General Hospital

Lesley Hall · Flinders University

Katherine Buzzard · Eastern Health

Kaylene M. Young · University of Tasmania

Fiona Mckay

Abstract

The STOP-MS trial has been acknowledged by the Therapeutics Goods Administration under the Clinical Trial Notification scheme (CT-2023-CTN-03 505-1) and is registered with the Australian and New Zealand Clinical Trial Registry (ACTRN12623000849695).

Topics & Keywords

Multiple Sclerosis Research Studies Polyomavirus and related diseases Viral Infections and Immunology Research

Publication Details

Published in: BMJ Neurology Open

Volume 7, Issue 2, pp. e001313-e001313

DOI: 10.1136/bmjno-2025-001313

Field-Weighted Citation Impact: 0.00

Command Palette

Study protocol for a multicentre, randomised, double-blinded, placebo-controlled, multi-arm, multi-stage, trial of SpironolacTone and famciclOovir in the treatment of Progressive Multiple Sclerosis to prevent disability progression: the STOP-MS trial

Authors

Abstract

Topics & Keywords

Publication Details